Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

Copenhagen, denmark, sept. 18, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, today announced the initiation of a novel pipeline program, evx-b3, an ai-designed vaccine candidate against an undisclosed bacterial pathogen. the new vaccine project will be a collaboration between evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations.
EVAX Ratings Summary
EVAX Quant Ranking